Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?

Am J Respir Crit Care Med. 2020 Dec 1;202(11):1587-1589. doi: 10.1164/rccm.202005-1611LE.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acetamides / therapeutic use
  • Adolescent
  • Antihypertensive Agents / therapeutic use
  • Asymptomatic Diseases
  • Bone Morphogenetic Protein Receptors, Type II / genetics*
  • Cardiac Catheterization
  • Disease Progression*
  • Dyspnea / physiopathology
  • Echocardiography
  • Exercise Tolerance
  • Female
  • Genetic Testing
  • Heterozygote
  • Humans
  • Male
  • Phenylpropionates / therapeutic use
  • Pulmonary Arterial Hypertension / diagnostic imaging
  • Pulmonary Arterial Hypertension / drug therapy
  • Pulmonary Arterial Hypertension / genetics
  • Pulmonary Arterial Hypertension / physiopathology*
  • Pyrazines / therapeutic use
  • Pyridazines / therapeutic use
  • Sildenafil Citrate / therapeutic use
  • Syncope / physiopathology
  • Vasodilator Agents / therapeutic use

Substances

  • Acetamides
  • Antihypertensive Agents
  • Phenylpropionates
  • Pyrazines
  • Pyridazines
  • Vasodilator Agents
  • selexipag
  • Sildenafil Citrate
  • BMPR2 protein, human
  • Bone Morphogenetic Protein Receptors, Type II
  • ambrisentan